POLB 001 cancer immunotherapy-induced CRS patent granted in Canada

Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (CRS) patent application from the Canadian patent office.

This represents the second national grant within Poolbeg's cancer immunotherapy-induced CRS patent family, following the grant by IP Australia announced in March 2026, and marks a further important milestone for the Company. This patent covers the use of any p38 MAPK inhibitor, including POLB 001, for the prevention of cancer immunotherapy-induced CRS, and is underpinned by proprietary data generated by Poolbeg.

Poolbeg filed its initial oncology patent applications in the UK in January 2023 before entering the international Patent Cooperation Treaty system in January 2024. This new patent grant was accelerated through the Patent Prosecution Highway, which enables expedited examination in participating countries where a favourable ruling has already been secured in another participating jurisdiction.

The Company's IP portfolio now spans both cancer immunotherapy-induced CRS and severe influenza across multiple jurisdictions, and Poolbeg continues to pursue protection in further territories. This grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's future value and appeal to potential partners.

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said:

This Canadian patent grant, coming shortly after our first oncology patent grant in Australia, further strengthens our IP position for POLB 001 and demonstrates the momentum we have built in expanding this patent family globally. With interim data from the TOPICAL trial expected this summer, we believe this patent grant further enhances the attractiveness of POLB 001 to prospective partners. We will continue to pursue coverage in other jurisdictions and look forward to updating shareholders on our progress.

*TOPICAL: Trial of Prevention of ImmunoCytokine Adverse events in Myeloma. A single-arm, open-label trial investigating POLB 001 as a potential preventative for CRS in relapsed/refractory multiple myeloma patients receiving the approved bispecific antibody, teclistamab, provided by Johnson and Johnson at no cost to Poolbeg.